Poster Session I - NOVEL TARGET/ EXPERIMENTAL FIDINGS TO CLINICAL TRANSLATION 06.00 - NOVEL TARGET/ EXPERIMENTAL FIDINGS TO CLINICAL TRANSLATION - 06.02 - GENETICS, OMICS AND BIOMARKERS P463 - ESOC25-2074 PLASMA PTAU217 AS A BIOMARKER FOR POST-STROKE COGNITIVE IMPAIRMENT PREDICTION: A NESTED CASE-CONTROL STUDY Elena Escriche 1 , Mara Molina 1 , Mnica Macas 2 , Inhar Esnaola 1 , Adrin Jimnez 1 , Miren Roldan 2 , Amaya Urdnoz-Casado 2,3 , Nuria Sobrino 4 , Celia Fernndez 4 , Idoia Rubio 1 , Roberto Muoz 1,3 , Maria Herrera Isasi 1,3 , Maite Mendioroz 1,2,3 1 Neurology Department, University Hospital of Navarra, Pamplona, Spain, 2 Neuroepigenetics Unit, Navarrabiomed-UPNA, Pamplona, Spain, 3 Redes de Investigacin Cooperativa Orientadas a Resultados en Salud (RICORS)- ISC III, Madrid, Spain, 4 Radiology Department, University Hospital of Navarra, Pamplona, Spain Background and Aims: Post-stroke cognitive impairment (PSCI) represents a significant complication affecting stroke survivors
Metabolism of fructose to oxalate and glycolate
$35 per vial with batch-matched COA in every box
A 2021 study in Gut found that long COVID patients had significantly reduced microbiome diversity and specific depletions in beneficial species, including Faecalibacterium prausnitzii and Bifidobacterium bacteria known for their anti-inflammatory and immune-regulatory properties
